Skip Navigation

Faculty Directory

Jeremy Sugarman, MD

  • Professor

Departmental Affiliations

Center & Institute Affiliations

Contact Information

1809 Ashland Avenue
Deering Hall 203
Baltimore, Maryland

410-614-5634
410-614-5360

Berman Institute of Bioethics Faculty Page

View Current Courses

Education

MD
MPH

Overview

Jeremy Sugarman, MD, MPH, MA is the Harvey M. Meyerhoff Professor of Bioethics and Medicine, professor of medicine, professor of Health Policy and Management, and deputy director for medicine of the Berman Institute of Bioethics at the Johns Hopkins University. He is an internationally recognized leader in the field of bioethics with particular expertise in applying empirical methods for evaluating and analyzing bioethical issues. His contributions to both bioethics and policy include his work on the ethics of informed consent, umbilical cord blood banking, stem cell research, international HIV prevention research, global health and research oversight.

Dr. Sugarman is the author of over 300 articles, reviews and book chapters. He has also edited or co-edited four books (Beyond Consent: Seeking Justice in Research; Ethics of Research with Human Subjects: Selected Policies and Resources; Ethics in Primary Care; and Methods in Medical Ethics). Dr. Sugarman is a member of the editorial boards of several academic journals.

Dr. Sugarman consults and speaks internationally on a range of issues related to bioethics. He served as senior policy and research analyst for the White House Advisory Committee on Human Radiation Experiments, consultant to the National Bioethics Advisory Commission, and Senior Advisor to the Presidential Commission for the Study of Bioethical Issues. He also served on the Maryland Stem Cell Research Commission.

He was the founding director of the Trent Center for Bioethics, Humanities and History of Medicine at Duke University where he was also a professor of medicine and philosophy. He is a faculty affiliate of the Kennedy Institute of Ethics at Georgetown University and an Academic Icon of the University of Malaya. He received a Doctor of Science, honoris causa, from New York Medical College.

Dr. Sugarman is a member of the Scientific and Research Advisory Board for the Canadian Blood Service, the Ethics and Public Policy Committees of the International Society for Stem Cell Research, chair of the Ethics Working Group of the HIV Prevention Trials Network, and co-leads the Ethics and Regulatory Core of the NIH Health Care Systems Research Collaboratory. He also co-chairs the Johns Hopkins’ Institutional Stem Cell Research Oversight Committee.

Honors and Awards

Dr. Sugarman has been elected as a member of the American Society of Clinical Investigation, Association of American Physicians, and the National Academy of Medicine (formerly the Institute of Medicine). He is a fellow of the American Association for the Advancement of Science, the American College of Physicians and the Hastings Center.

  • Ethics
  • Medical Ethics
  • Bioethics
  • Research Ethics

Some recent publications related to global health ethics.

  • Sugarman J, Trumble I, Hamilton E, Sarasvita R, Dumchev K, Viet H, Hoffman I, Miller W, Hanscom B. Reported participation benefits in international HIV prevention research with people who inject drugs. Ethics Hum Res 2019; 41:28-34. doi: 10.1002/eahr.500030. PMID: 31541541.
  • Sugarman J, Celum CL, Donnell D, Mayer KH. Ethical considerations for new HIV prevention trials. Lancet HIV 2019; 6:e489-e491. doi: 10.1016/S2352-3018(19)30184-5. PMID: 31256635.
  • Sugarman J, Lin L, Baeten JM, Palanee-Phillips T, Brown ER, Matovu Kiweewa F, Mgodi NM, Nair G, Siva S, Seils DM, Weinfurt KP; MTN-020/ASPIRE Study Team. Preventive misconception and risk behaviors in a multinational HIV prevention trial. AJOB Empir Bioeth. 2019 Apr 19:1-9. doi: 10.1080/23294515.2019.1593257. [Epub ahead of print] PMID: 31002583.
  • Sugarman J, Barnes M, Rose S, Dumchev K, Sarasvita R, Viet HT, Zeziulin O, Susami H, Go V, Hoffman I, Miller W. Development and implementation of participant safety plans for international research with stigmatized populations. Lancet HIV 2018; 5: e468-e472. doi: 1016/S2352-3018(18)30073-0. PMID: 29950284.
  • Sipp D, Caulfield T, Kaye J, Barfoot J, Blackburn C, Chan S, De Luca M, Kent A, McCabe C, Munsie M, Sleeboom-Faulkner M, Sugarman J, van Zimmeren E, Zarzeczny A, Rasko JE. Marketing of unproven stem cell-based interventions: a call to action. Sci Transl Med 2017; 9: eaag0426. PMID: 28679655.